Kineta, Inc. - KA STOCK NEWS

Kineta, a clinical-stage biotech firm, announced its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, held November 6-10, 2024, in Houston, Texas and virtually. The poster, presented by Dr. Jason Henry on November 8, 2024, will reveal new clinical data from an ongoing Phase 1/2 trial of KVA12123, Kineta’s VISTA blocking immunotherapy, alone and with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. The presentation is scheduled for 9:00 A.M. – 7:00 P.M. Central Time at Exhibit Halls AB, George R. Brown Convention Center. Abstract titles are available on the SITC website, and posters will be accessible on Kineta’s website post-conference.

Kineta, Inc. (OTC Pink: KANT) announced that TuHURA Biosciences Inc has extended their exclusivity and right of first offer agreement for Kineta's VISTA blocking antibody KVA12123. This extension is part of the agreement entered in July 2024, allowing TuHURA to extend their rights for up to two 10-day periods, with Kineta receiving $150,000 for each extension.

Kineta reopened the Phase 1 clinical study in August 2024 and is currently enrolling patients with advanced solid tumor cancers. The company aims to complete enrollment by year-end 2024. KVA12123 has shown strong tumor growth inhibition in preclinical models and may be effective for various cancer types, including NSCLC, colorectal, renal cell carcinoma, head and neck, and ovarian cancer.

Kineta continues to explore strategic alternatives to maximize shareholder value, with more information expected later this year.

Kineta, a clinical-stage biotech firm, announced its transition from Nasdaq to the OTC Pink Open Market, trading under the ticker KANT as of September 19, 2024. This move follows Nasdaq's decision to delist Kineta due to non-compliance with the $1.00 minimum bid price and $2.5 million stockholders' equity requirements. Shareholders' investments remain secure and tradable. Kineta continues its focus on strategic alternatives and its KVA12123 Phase 1 study, which is open for new patient enrollment. Additionally, Kineta has an exclusivity agreement with TuHURA Biosciences, providing a $5 million nonrefundable payment and cooperation on the VISTA-101 Phase 1/2 trial.

Kineta (Nasdaq: KA) has reopened enrollment for its VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumor cancer. The trial includes a monotherapy arm and a combination arm with Merck's KEYTRUDA®. To date, 30 patients have been enrolled, and Kineta expects full enrollment by end of 2024. Initial results showed partial response and stable disease in combination cohorts and durable stable disease in monotherapy cohorts. KVA12123 demonstrated a favorable safety profile with no dose-limiting toxicities or cytokine release syndrome.

Kineta recently entered an exclusivity agreement with TuHURA Biosciences, receiving a $5 million payment. TuHURA has an exclusive right to acquire Kineta's KVA12123-related assets until October 1, 2024, subject to extension.

TuHURA Biosciences and Kintara Therapeutics (Nasdaq: KTRA) announced that Kineta Inc. has reopened enrollment for the VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumor cancer. The trial has enrolled 30 out of 39 projected patients, including a monotherapy arm and a combination arm with Merck's KEYTRUDA®. Kineta expects full enrollment by the end of 2024.

KVA12123 has shown promising initial results, including partial response and stable disease in combination cohorts and durable stable disease in monotherapy cohorts. The drug has demonstrated a favorable safety profile with no dose-limiting toxicities or cytokine release syndrome. TuHURA is currently in due diligence for the potential acquisition of KVA12123 from Kineta, following a $5 million nonrefundable payment and an exclusive negotiation agreement.

Kineta has entered an exclusivity and right of first offer agreement with TuHURA Biosciences for its KVA12123 immuno-oncology drug program. Under the agreement, TuHURA has the exclusive right to negotiate the acquisition of Kineta's assets, patents, and development program related to KVA12123. This right is valid until October 1, 2024, with possible extension. Kineta will receive a nonrefundable $5 million payment from TuHURA. KVA12123, a VISTA blocking monoclonal antibody, is currently in Phase 1/2 clinical trials in the US for advanced solid tumors, showing good tolerance and no significant toxicities. Further data are expected in Q4 2024.

TuHURA Biosciences has entered into an Exclusivity and Right of First Offer Agreement with Kineta for the potential acquisition of the anti-VISTA antibody KVA12123 and related assets. KVA12123 targets VISTA, a checkpoint on quiescent T-cells, to reverse immune suppression and remodel the tumor microenvironment. This inhibitor is currently in Phase 1/2 clinical trials, showing favorable safety and tolerability. Concurrently, TuHURA secured a $5 million investment from an existing shareholder to support its Phase 3 trial and ADC development. The agreement includes a payment of $2.5 million at signing, with an additional $2.5 million due by July 15, 2024, and a 90-day exclusivity period.

Kineta (Nasdaq: KA) announced its Q1 2024 financial results and updates on the Phase 1/2 VISTA-101 clinical trial for its immunotherapy, KVA12123, targeting advanced solid tumors.

The trial showed partial responses and stable disease in combination cohorts, and durable stable disease in monotherapy cohorts. Safety and tolerability are favorable with no limiting toxicities or cytokine release syndrome observed.

Corporate restructuring in February 2024 aimed to reduce expenses and preserve cash, including workforce cuts and suspending new patient enrollment in the trial. The company received a $500,000 investment but is pursuing litigation for unfulfilled funding from other investors.

Financially, Kineta reported a net loss of $10.2 million for Q1 2024 compared to $6.5 million in Q1 2023. Cash reserves dropped to $1.8 million from $5.8 million at the end of 2023, raising concerns about the company's ability to continue as a going concern.